Publication:
Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies

Thumbnail Image
Files
Interim2017_18InfluenzaSeasonal_2018.pdf (533.4 KB)
Identifiers
URI: http://hdl.handle.net/20.500.12105/8992
ISSN: 1560-7917
DOI: 10.2807/1560-7917.ES.2018.23.9.18-00086
Publication date
2018
Authors
Rondy, Marc
Kissling, Esther
Emborg, Hanne-Dorthe
Pebody, Richard
Trebbien, Ramona
McMenamin, Jim
Valenciano, Marta
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
European Centre for Disease Prevention and Control (ECDC)
Metrics
Google Scholar
Export
MarcXML METS
Research Projects
Organizational Units
Journal Issue
Abstract
Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
Description
Keywords
Europe Case control study Influenza Influenza vaccination Influenza vaccine effectiveness Multicentre study
MeSH Terms
Adolescent Adult Aged Child Child, Preschool Europe European Union Female Humans Infant Infant, Newborn Influenza A Virus, H1N1 Subtype Influenza A Virus, H3N2 Subtype Influenza B virus Influenza Vaccines Influenza, Human Male Middle Aged Pandemics Treatment Outcome Vaccination Seasons
DeCS Terms
Bibliographic citation
Euro Surveill. 2018 Mar;23(9):18-00086.
Collections
Centro Nacional de Epidemiología (CNE)
Centro Nacional de Microbiología (CNM)
IdiSNA - Instituto de Investigación Sanitaria de Navarra (Navarra)
Publisher version
https://doi.org/10.2807/1560-7917.ES.2018.23.9.18-00086
Document type
journal article